Regeneron Pharmaceuticals has announced that its newly approved gene therapy, Otarmeni, designed to treat a rare genetic form of hearing loss, will be distributed free of charge to patients in the United States. However, the biotechnology firm has yet to determine the pricing structure for international markets, with company leadership indicating that overseas nations will […]